Journal
JOURNAL OF CONTROLLED RELEASE
Volume 256, Issue -, Pages 182-192Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.04.014
Keywords
Supramolecular nanoparticles; Dipeptides; Salmon calcitonin; Self-assembly; Controlled release
Funding
- National Natural Science Foundation of China [21534008, 51322303, 21103016]
- Key Laboratory for NeuroInformation of Ministry of Education [ZYGX2015J144]
Ask authors/readers for more resources
Salmon calcitonin (sCT) is a therapeutic polypeptide drug widely used to treat bone diseases such as osteoporosis (more than 200 million patients all over the world). The half-life of sCT is very short (similar to 1 h), thus various delivery systems have been developed for sCT in order to avoid frequent injections. However, most delivery systems use polymeric materials, which may limit their applications in clinic formulations due to the biocompatibility issue. We observed that a very simple dipeptide (Asp-Phe, DF) was co-assembled with sCT into supramolecular nanoparticles. These nanoparticles can significantly prolong the acting time of sCT to beyond one month after just a single subcutaneous injection. The assembling and releasing mechanisms were thoroughly investigated by both in vitro and in vivo methods, as well as by molecular dynamics simulations. This work provides an alternative strategy of designing protein/peptide drug delivery systems with long-lasting therapeutic effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available